GXI has been the subject of a number of other research reports. Credit Suisse Group set a €80.00 ($94.12) price objective on shares of Gerresheimer AG and gave the company a buy rating in a research note on Tuesday. Hauck & Aufhaeuser set a €63.50 ($74.71) price objective on shares of Gerresheimer AG and gave the company a neutral rating in a research note on Thursday, September 21st. Goldman Sachs Group, Inc. (The) set a €73.00 ($85.88) price objective on shares of Gerresheimer AG and gave the company a neutral rating in a research note on Friday, June 30th. Berenberg Bank set a €75.00 ($88.24) price objective on shares of Gerresheimer AG and gave the company a buy rating in a research note on Monday, September 4th. Finally, Commerzbank Ag set a €73.00 ($85.88) price objective on shares of Gerresheimer AG and gave the company a neutral rating in a research note on Thursday, July 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of €73.14 ($86.05).
Gerresheimer AG (ETR:GXI) traded down 2.10% on Wednesday, hitting €63.99. 320 shares of the stock traded hands. Gerresheimer AG has a 12-month low of €59.97 and a 12-month high of €79.47. The stock has a 50-day moving average of €65.32 and a 200-day moving average of €70.43. The firm has a market cap of €2.01 billion and a price-to-earnings ratio of 17.73.
TRADEMARK VIOLATION WARNING: “Gerresheimer AG (GXI) Given a €99.40 Price Target at J P Morgan Chase & Co” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/10/12/gerresheimer-ag-gxi-given-a-99-40-price-target-at-j-p-morgan-chase-co.html.
Gerresheimer AG Company Profile
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer AG and related companies with MarketBeat.com's FREE daily email newsletter.